Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2018 > Farxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE

Farxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE

Read also

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

Teva Pharmaceutical Industries Limited recently announced that the FDA has approved expanded use of its branded product, Uzedy (risperidone).

FDA Breakthrough Designation Signals New Therapeutic Avenue in R/R MCL

FDA Breakthrough Designation Signals New Therapeutic Avenue in R/R MCL

The FDA has granted breakthrough therapy designation (BTD) to the investigational B-cell lymphoma 2 (BCL2) inhibitor sonrotoclax (BGB-11417) for the treatment of adult patients...

Preclinical study identifies genetic misfire in lupus

Preclinical study identifies genetic misfire in lupus

Cedars-Sinai investigators have identified a "molecular switch" on a gene strongly associated with the autoimmune disease lupus, which appears to propel immune cells into overdrive, attackin...

Tvardi Therapeutics’ stock crashes on Phase II IPF flop

Tvardi Therapeutics’ stock crashes on Phase II IPF flop

Tvardi Therapeutics’ stock has crashed more than 80% after the company revealed that its idiopathic pulmonary fibrosis (IPF) candidate flunked in a Phase II trial.